Drugs / 18F-Fluorothymidine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02891616 | Oct 2016 → Dec 2017 | melanoma | Washington University School of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 21 trial | ||||||
| Phase 2 | NCT00721799 | Mar 2008 → Dec 2014 | laryngeal neoplasm, neoplasm of oropharynx, oral cavity neoplasm | University of Iowa | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Fluorothymidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00721799 ↗ |
| Modality | Diagnostic / imaging agent | “a new imaging study, Positron Emission Tomography with F-18 Fluorothymidine (FLT PET)” NCT00721799 ↗ |
| Route | Intravenous | “administered once intravenously” NCT00721799 ↗ |